Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Mobia Medical Raises $150 Million in Initial Public Offering
Latham & Watkins LLP has advised Mobia Medical, Inc. Cleary Gottlieb has represented the underwriters. Mobia Medical, Inc., a commercial-stage medical device company, completed its initial...
Vaxcyte Completes $632.5 Million Public Offering of Common Stock
Skadden has advised Vaxcyte, Inc. Latham & Watkins LLP has advised the underwriters. Vaxcyte, Inc. has completed the closing of an underwritten public offering of 12,650,000...
Vir Biotechnology Completes $172.5 Million Public Offering of Common Stock
Gunderson Dettmer, with support from Ropes & Gray LLP, Sheppard, Mullin, Richter & Hampton LLP, and Fox Rothschild LLP, has advised Vir Biotechnology. Latham & Watkins...
Alcon Inc’s Acquisition of LENSAR Inc
Norton Rose Fulbright represented Alcon Inc., Latham & Watkins represented LENSAR, Inc. in the transaction. Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
Alpine Immune Sciences’ $150 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Guardant Health’s Upsized Public Offering of Common Stock
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...